Sono-Tek Corporation (SOTK) Fair Value & Analysis
Technology · US · Market cap $84.1M
Fair value as of: Jun 24, 2026
Analysis
Sono-Tek Corporation (SOTK) currently trades at $5.35, while our model-based Fair Value estimate is $2.30 — implying the stock looks roughly 57.0% overvalued today. We read business quality at 97/100 (high quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Sono-Tek Corporation designs and manufactures ultrasonic coating systems for applying on parts and components for the microelectronics/electronics, alternative energy, medical, industrial, and research and development/other markets. The company offers custom-engineered ultrasonic coating systems; and nozzles and generators. It also provides integrated multi-axis coating systems, integrated coating systems, fluxing systems, OEM systems, and other related systems. In addition, the company offers surface coating solutions and application consulting services. It markets and distributes its products through direct sales personnel, select independent distributors, and sales representatives. The company operates in the United States, Canada, the Asia Pacific, Europe, the Middle East, Asia, and Latin America. Sono-Tek Corporation was incorporated in 1975 and is headquartered in Milton, New York.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Sono-Tek Corporation (SOTK) undervalued?
What is the fair value of SOTK?
What is the quality score of SOTK?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.